Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 2 crawled date : 2021 - 12 - 14 save search
PharmaJet Partner Nykode Therapeutics Announces Phase 1/2 Clinical Trial With Next Generation DNA-Based COVID-19 Vaccine Candidates
Published: 2021-12-14 (Crawled : 15:00) - biospace.com/
NKTR | News | $1.265 -4.17% -4.35% 4.7M
|
Health Technology
|
| O: 2.3%
H: 3.69%
C: 1.77%
covid-19 trial therapeutics covid phase 1 vaccine phase 2
Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion
Published: 2021-12-14 (Crawled : 14:00) - globenewswire.com
RMTI | $1.46 -1.35% -1.37% 82K
|
Health Technology
|
| O: 7.85%
H: 3.49%
C: -8.37%
fda phase 2 application trial
Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa
Published: 2021-12-14 (Crawled : 13:30) - oramed.com
ORMP A | $2.265 2.96% 2.87% 110K
|
Health Technology
|
| O: -3.6%
H: 1.87%
C: -2.4%
covid-19 trial covid phase 1 vaccine enroll phase 2 africa
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
Published: 2021-12-14 (Crawled : 13:00) - biospace.com/
ATAI | $1.85 -3.14% -3.24% 940K
|
Manufacturing
|
| O: -2.67%
H: 0.0%
C: 0.0%
rl-007 phase 2 schizophrenia air trial life science biomarkers phase 2b
Antios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
ABUS | $2.725 -0.18% -0.18% 930K
|
Health Technology
|
| O: -2.52%
H: 7.76%
C: -2.59%
ati-2173 phase 2 hepatitis biopharma ab-729 trial therapeutics infection infections phase 2b chronic hepatitis b
Alterity Therapeutics Announces First Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
ATHE | $2.04 -4.67% -4.9% 54K
|
Health Technology
|
| O: 0.24%
H: 3.2%
C: 0.42%
ath434 phase 2 trial therapeutics authorization
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Published: 2021-12-14 (Crawled : 12:30) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 1.99%
H: 0.0%
C: 0.0%
covid-19 treatment phase 2 risk phase 2/3 covid antiviral results
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
Published: 2021-12-14 (Crawled : 12:00) - eyegatepharma.com
KPRX | $0.502 -1.57% -1.59% 49K
|
Manufacturing
|
| O: -8.7%
H: 0.0%
C: 0.0%
kio-101 dry eye phase 2 eye eye disease disease topline
New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 6.02%
H: 2.03%
C: -0.29%
phase 1 results phase 2 phase 3
Innovent Announces Pivotal Phase 2 Results for Parsaclisib (PI3Kδ inhibitor) Presented at ASH 2021 Show Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma
Published: 2021-12-14 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.82%
H: 0.92%
C: 0.66%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 3.76%
H: 3.79%
C: 1.89%
phase 2 phase 2 results results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.